Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Clinical trial NCT03544125 · COMPLETED

Trial details

NCT number: NCT03544125
Sponsor: OHSU Knight Cancer Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Anatomic Stage IV Breast Cancer AJCC v8 Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Prognostic Stage IV Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma

Start date: 2018-05-03
Primary completion: 2018-08-07
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.